Pharmacokinetics, biodistribution and antitumour effects of Sclerotium rolfsii lectin in mice

Anupama S,; Laha,Preeti; Sharma,Mamta; Pathak,Kamal; Bane,Sanjay; Ingle,Arvind  D.; Gota,Vikram; Kalraiya,Rajiv  D.; Yu,Lu-Gang; Rhodes,Jonathan  M.; Swamy,Bale  M.; Inamdar,Shashikala  R.

doi:10.3892/or.2017.5545

Pharmacokinetics, biodistribution and antitumour effects of Sclerotium rolfsii lectin in mice

Authors:
- Anupama S
- Preeti Laha
- Mamta Sharma
- Kamal Pathak
- Sanjay Bane
- Arvind D. Ingle
- Vikram Gota
- Rajiv D. Kalraiya
- Lu-Gang Yu
- Jonathan M. Rhodes
- Bale M. Swamy
- Shashikala R. Inamdar
View Affiliations

Affiliations: Department of Studies in Biochemistry, Karnatak University, Dharwad 580003, India, Advanced Centre for Treatment, Research and Education in Cancer, Kharghar, Navi Mumbai 410210, India, Department of Gastroenterology, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3BX, UK
Published online on: April 3, 2017 https://doi.org/10.3892/or.2017.5545
Pages: 2803-2810

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sclerotium rolfsii lectin (SRL) is a lectin isolated from the fungus Sclerotium rolfsii and has exquisite binding specificity towards the oncofetal Thomsen-Friedenreich antigen (TF-Ag; Galβ1-3GalNAcα-O-Ser/Thr) and its derivatives. Previous studies have shown that SRL inhibits the proliferation of human colon, breast and ovarian cancer cells in vitro and suppresses tumour growth in mice when introduced intratumourally. The present study assessed the effect of SRL on tumour growth when introduced intraperitoneally in BALB/c nude mice and investigated the pharmacokinetics and biodistribution of SRL in Swiss albino mice. When 9 doses of SRL (30 mg/kg body weight/mice) was administered to BALB/c nude mice bearing human colon cancer HT-29 xenografts, a substantial reduction in tumour size was observed. A 35.8% reduction in tumour size was noted in the treated animals after 17 days. SRL treatment also inhibited angiogenesis, and the tumours from the treated animals were observed to carry fewer blood vessels and express less angiogenesis marker protein CD31, than that from the control animals. Pharmacokinetics and biodistribution analysis revealed that SRL was detected in the serum after 1 h and its level peaked after 24 h. SRL was not detected in any of the organs apart from the kidney where a trace amount was detected after 24 h of SRL injection. No significant changes were observed in any of the biochemical parameters tested including SGOT, SGPT, LDH, CREAT and BUN in the SRL-treated mice compared to these levels in the controls. This suggests that SRL has good potential to be developed as a therapeutic agent for cancer treatment and warrant further investigations in vivo and subsequent clinical trials.

View Figures

View References

1	World Health Organization: Global Health Observatory data repository 2011. Number of deaths (world) by cause; http://apps.who.int/gho/data/node.main.CODWORLD?lang=enAccessed. October 31–2013
2	American Cancer Society: Cancer Facts & Figures 2015. US Mortality Data, National Center for Health Statistic Center for Disease, Control & Prevention. 2015.https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2015.html
3	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin MD, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2014. View Article : Google Scholar : PubMed/NCBI
4	Bies C, Lehr CM and Woodley JF: Lectin-mediated drug targeting: History and applications. Adv Drug Deliv Rev. 56:425–435. 2004. View Article : Google Scholar : PubMed/NCBI
5	Yu LG, Fernig DG, White MR, Spiller DG, Appleton P, Evans RC, Grierson I, Smith JA, Davies H, Gerasimenko OV, et al: Edible mushroom (Agaricus bisporus) lectin, which reversibly inhibits epithelial cell proliferation, blocks nuclear localization sequence-dependent nuclear protein import. J Biol Chem. 274:4890–4899. 1999. View Article : Google Scholar : PubMed/NCBI
6	Yu L, Fernig DG, Smith JA, Milton JD and Rhodes JM: Reversible inhibition of proliferation of epithelial cell lines by Agaricus bisporus (edible mushroom) lectin. Cancer Res. 53:4627–4632. 1993.PubMed/NCBI
7	Zhao C, Sun H, Tong X and Qi Y: An antitumour lectin from the edible mushroom Agrocybe aegerita. Biochem J. 374:321–327. 2003. View Article : Google Scholar : PubMed/NCBI
8	Jiang S, Chen Y, Wang M, Yin Y, Pan Y, Gu B, Yu G, Li Y, Wong BH, Liang Y, et al: A novel lectin from Agrocybe aegerita shows high binding selectivity for terminal N-acetylglucosamine. Biochem J. 443:369–378. 2012. View Article : Google Scholar : PubMed/NCBI
9	Wang HX, Liu WK, Ng TB, Ooi VE and Chang ST: The immunomodulatory and antitumor activities of lectins from the mushroom Tricholoma mongolicum. Immunopharmacology. 31:205–211. 1996. View Article : Google Scholar : PubMed/NCBI
10	Li YR, Liu QH, Wang HX and Ng TB: A novel lectin with potent antitumor, mitogenic and HIV-1 reverse transcriptase inhibitory activities from the edible mushroom Pleurotus citrinopileatus. Biochim Biophys Acta. 1780:51–57. 2008. View Article : Google Scholar : PubMed/NCBI
11	Zhang GQ, Sun J, Wang HX and Ng TB: A novel lectin with antiproliferative activity from the medicinal mushroom Pholiota adiposa. Acta Biochim Pol. 56:415–421. 2009.PubMed/NCBI
12	Swamy BM, Hegde GV, Naik RS and Inamdar SR: T-antigen binding lectin from the phytopathogenic fungus Sclerotium rolfsii. Lect. Biol Biochem Clin Biochem. 15:45–55. 2001.
13	Chachadi VB, Inamdar SR, Yu LG, Rhodes JM and Swamy BM: Exquisite binding specificity of Sclerotium rolfsii lectin toward TF-related O-linked mucin-type glycans. Glycoconj J. 28:49–56. 2011. View Article : Google Scholar : PubMed/NCBI
14	Yu LG: The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression. Glycoconj J. 24:411–420. 2007. View Article : Google Scholar : PubMed/NCBI
15	Leonidas DD, Swamy BM, Hatzopoulos GN, Gonchigar SJ, Chachadi VB, Inamdar SR, Zographos SE and Oikonomakos NG: Structural basis for the carbohydrate recognition of the Sclerotium rolfsii lectin. J Mol Biol. 368:1145–1161. 2007. View Article : Google Scholar : PubMed/NCBI
16	Inamdar SR, Savanur MA, Eligar SM, Chachadi VB, Nagre NN, Chen C, Barclays M, Ingle A, Mahajan P, Borges A, et al: The TF-antigen binding lectin from Sclerotium rolfsii inhibits growth of human colon cancer cells by inducing apoptosis in vitro and suppresses tumor growth in vivo. Glycobiology. 22:1227–1235. 2012. View Article : Google Scholar : PubMed/NCBI
17	Savanur MA, Eligar SM, Pujari R, Chen C, Mahajan P, Borges A, Shastry P, Ingle A, Kalraiya RD, Swamy BM, et al: Sclerotium rolfsii lectin induces stronger inhibition of proliferation in human breast cancer cells than normal human mammary epithelial cells by induction of cell apoptosis. PLoS One. 9:e1101072014. View Article : Google Scholar : PubMed/NCBI
18	Eligar SM, Pujari R, Swamy BM, Shastry P and Inamdar SR: Sclerotium rolfsii lectin inhibits proliferation and induces apoptosis in human ovarian cancer cell line PA-1. Cell Prolif. 45:397–403. 2012. View Article : Google Scholar : PubMed/NCBI
19	Barkeer S, Guha N, Hothpet V, Adavigowda Saligrama D, Hegde P, Padmanaban A, Yu LG, Swamy BM and Inamdar SR: Molecular mechanism of anticancer effect of Sclerotium rolfsii lectin in HT29 cells involves differential expression of genes associated with multiple signaling pathways: A microarray analysis. Glycobiology. 25:1375–1391. 2015. View Article : Google Scholar : PubMed/NCBI
20	Barkeer S, Gudihal R, Eligar SM, Hegde P, Lu GY, Bale MS and Inamdar SR: Identification and characterization of Sclerotium rolfsii lectin (SRL) binding proteins from human colon epithelial cancer HT29 cells. Translational Biomedicine ISSN 2172-0479. 2015.
21	Sharma SK, Pedley RB, Bhatia J, Boxer GM, El-Emir E, Qureshi U, Tolner B, Lowe H, Michael NP, Minton N, et al: Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. Clin Cancer Res. 11:814–825. 2005.PubMed/NCBI
22	Vallespí MG, Pimentel G, Cabrales-Rico A, Garza J, Oliva B, Mendoza O, Gomez Y, Basaco T, Sánchez I, Calderón C, et al: Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse models. J Pept Sci. 20:850–859. 2014. View Article : Google Scholar : PubMed/NCBI
23	Ingle AD and Hosetti BB: Use of immuno-compromised mouse model for establishment and study of human animal tumours. Indian J Vet Pathol. 34:156–161. 2010.
24	Simpson RJ: Homogenization of mammalian tissue. Cold Spring Harb Protoc pdb prot 5455. 2010.https://doi.org/10.1101/pdb.prot5455https://doi.org/10.1101/pdb.prot5455. View Article : Google Scholar
25	Burden DW: Guide to the Homogenization of Biological Samples. Random Primers. 7:2008.1–14, 2008. http://www.opsdiagnostics.com/notes/ranpri/Homogenization%20Guide%20ver.pdf
26	Hartmann C, Smeyers-Verbeke J, Massart DL and McDowall RD: Validation of bioanalytical chromatographic methods. J Pharm Biomed Anal. 17:193–218. 1998. View Article : Google Scholar : PubMed/NCBI
27	Ahn JE, Karlsson MO, Dunne A and Ludden TM: Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 35:401–421. 2008. View Article : Google Scholar : PubMed/NCBI
28	Jusko WJ: Use of pharmacokinetic data below lower limit of quantitation values. Pharm Res. 29:2628–2631. 2012. View Article : Google Scholar : PubMed/NCBI
29	Beal SL: Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 28:481–504. 2001. View Article : Google Scholar : PubMed/NCBI
30	Sallam H, El-Serafi I, Meijer L and Hassan M: Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice. BMC Pharmacol Toxicol. 14:502013. View Article : Google Scholar : PubMed/NCBI
31	Khlebtsov N and Dykman L: Biodistribution and toxicity of engineered gold nanoparticles: A review of in vitro and in vivo studies. Chem Soc Rev. 40:1647–1671. 2011. View Article : Google Scholar : PubMed/NCBI
32	Ghazarian H, Idoni B and Oppenheimer SB: A glycobiology review: Carbohydrates, lectins and implications in cancer therapeutics. Acta Histochem. 113:236–247. 2011. View Article : Google Scholar : PubMed/NCBI
33	Campbell BJ, Finnie IA, Hounsell EF and Rhodes JM: Direct demonstration of increased expression of Thomsen-Friedenreich (TF) antigen in colonic adenocarcinoma and ulcerative colitis mucin and its concealment in normal mucin. J Clin Invest. 95:571–576. 1995. View Article : Google Scholar : PubMed/NCBI
34	Singh R, Campbell BJ, Yu LG, Fernig DG, Milton JD, Goodlad RA, FitzGerald AJ and Rhodes JM: Cell surface-expressed Thomsen-Friedenreich antigen in colon cancer is predominantly carried on high molecular weight splice variants of CD44. Glycobiology. 11:587–592. 2001. View Article : Google Scholar : PubMed/NCBI
35	Hanisch FG and Baldus SE: The Thomsen-Friedenreich (TF) antigen: A critical review on the structural, biosynthetic and histochemical aspects of a pancarcinoma-associated antigen. Histol Histopathol. 12:263–281. 1997.PubMed/NCBI
36	Almogren A, Abdullah J, Ghapure K, Ferguson K, Glinsky VV and Rittenhouse-Olson K: Anti-Thomsen-Friedenreich-Ag (anti-TF-Ag) potential for cancer therapy. Front Biosci (Schol Ed). 4:840–863. 2012.PubMed/NCBI
37	Belov L, Zhou J and Christopherson RI: Cell surface markers in colorectal cancer prognosis. Int J Mol Sci. 12:78–113. 2010. View Article : Google Scholar : PubMed/NCBI
38	Singh R, Subramanian S, Rhodes JM and Campbell BJ: Peanut lectin stimulates proliferation of colon cancer cells by interaction with glycosylated CD44v6 isoforms and consequential activation of c-Met and MAPK: Functional implications for disease-associated glycosylation changes. Glycobiology. 16:594–601. 2006. View Article : Google Scholar : PubMed/NCBI
39	Yau T, Dan X, Ng CC and Ng TB: Lectins with potential for anti-cancer therapy. Molecules. 20:3791–3810. 2015. View Article : Google Scholar : PubMed/NCBI
40	Mitchell BS and Schumacher U: The use of the lectin Helix pomatia agglutinin (HPA) as a prognostic indicator and as a tool in cancer research. Histol Histopathol. 14:217–226. 1999.PubMed/NCBI
41	Peiris D, Ossondo M, Fry S, Loizidou M, Smith-Ravin J and Dwek MV: Identification of O-linked glycoproteins binding to the lectin Helix pomatia agglutinin as markers of metastatic colorectal cancer. PLoS One. 10:e01383452015. View Article : Google Scholar : PubMed/NCBI
42	Liu B, Wu JM, Li J, Liu JJ, Li WW, Li CY, Xu HL and Bao JK: Polygonatum cyrtonema lectin induces murine fibrosarcoma L929 cell apoptosis and autophagy via blocking Ras-Raf and PI3K-Akt signaling pathways. Biochimie. 92:1934–1938. 2010. View Article : Google Scholar : PubMed/NCBI
43	Wang SY, Yu QJ, Bao JK and Liu B: Polygonatum cyrtonema lectin, a potential antineoplastic drug targeting programmed cell death pathways. Biochem Biophys Res Commun. 406:497–500. 2011. View Article : Google Scholar : PubMed/NCBI
44	Kang TB, Song SK, Yoon TJ, Yoo YC, Lee KH, Her E and Kim JB: Isolation and characterization of two Korean mistletoe lectins. J Biochem Mol Biol. 40:959–965. 2007.PubMed/NCBI
45	Yoon TJ, Yoo YC, Kang TB, Song SK, Lee KB, Her E, Song KS and Kim JB: Antitumor activity of the Korean mistletoe lectin is attributed to activation of macrophages and NK cells. Arch Pharm Res. 26:861–867. 2003. View Article : Google Scholar : PubMed/NCBI
46	Rostock M, Huber R, Greiner T, Fritz P, Scheer R, Schueler J and Fiebig HH: Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts. Anticancer Res. 25:1969–1975. 2005.PubMed/NCBI
47	Miyagi T, Takehara T, Tatsumi T, Suzuki T, Jinushi M, Kanazawa Y, Hiramatsu N, Kanto T, Tsuji S, Hori M, et al: Concanavalin a injection activates intrahepatic innate immune cells to provoke an antitumor effect in murine liver. Hepatology. 40:1190–1196. 2004. View Article : Google Scholar : PubMed/NCBI
48	Lei HY and Chang CP: Lectin of Concanavalin A as an anti-hepatoma therapeutic agent. J Biomed Sci. 16:102009. View Article : Google Scholar : PubMed/NCBI